2024
ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
Arrillaga-Romany I, Gardner S, Odia Y, Aguilera D, Allen J, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit K, Graber J, Haggiagi A, Harrison R, Kheradpour A, Kilburn L, Kurz S, Lu G, MacDonald T, Mehta M, Melemed A, Nghiemphu P, Ramage S, Shonka N, Sumrall A, Tarapore R, Taylor L, Umemura Y, Wen P. ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma. Journal Of Clinical Oncology 2024, 42: 1542-1552. PMID: 38335473, PMCID: PMC11095894, DOI: 10.1200/jco.23.01134.Peer-Reviewed Original ResearchConceptsH3 K27M-mutant diffuse midline gliomaDiffuse midline gliomaDuration of responseTime to responseHigh-grade gliomasLow-grade gliomasMidline gliomaMedian duration of responseMedian time to responseTreatment-emergent adverse eventsEnd pointsBlinded independent central reviewCorticosteroid dose reductionIndependent central reviewSecondary end pointsClinically meaningful efficacyRadiographic end pointsSpinal tumorsDose reductionDismal prognosisCentral reviewPerformance scoresCorticosteroid responseResponse assessmentAdverse events
2019
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma
Spino M, Kurz S, Chiriboga L, Serrano J, Zeck B, Sen N, Patel S, Shen G, Vasudevaraja V, Tsirigos A, Suryadevara C, Frenster J, Tateishi K, Wakimoto H, Jain R, Riina H, Nicolaides T, Sulman E, Cahill D, Golfinos J, Isse K, Saunders L, Zagzag D, Placantonakis D, Snuderl M, Chi A. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase–mutant Glioma. Clinical Cancer Research 2019, 25: 1261-1271. PMID: 30397180, PMCID: PMC7365589, DOI: 10.1158/1078-0432.ccr-18-2312.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedBenzodiazepinonesBrainDNA MethylationFemaleGene Expression Regulation, NeoplasticGenotypeGliomaHumansImmunoconjugatesIntracellular Signaling Peptides and ProteinsIsocitrate DehydrogenaseLigandsMaleMembrane ProteinsMolecular Targeted TherapyMutationNeoplasm Recurrence, LocalReceptors, NotchRNAConceptsGlioma molecular subtypesAntibody-drug conjugatesMolecular subtypesCell surface tumor-associated antigensTumor-associated antigensWild-type glioblastomaAntigen-dependent mannerLow-grade gliomasRova-TRecurrent tumorsDLL3 expressionRovalpituzumab tesirineNontumor brain tissuesNontumor brainMutant gliomasTherapeutic strategiesCell viability assayGliomaRNA levelsDLL3TumorspheresTherapeutic targetIHCTCGA dataWild-type